BPC-157 - Livewell Pharmaceuticals

BPC-157 originated in Croatia in 1992 under the guidance of Dr. Predrag Sikiric. A synthetic peptide based on gastric proteins, it was explored for use in regenerative medicine. The Croatian firm Pliva supported its early development, which progressed through preclinical stages before being halted in 2005 due to lack of funds. Merck later tried to obtain rights, but their attempt failed. Though never adopted into pharmaceuticals, the compound became widely sold in research circles, with Diagen of Slovenia leading its distribution.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about BPC-157 by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.